Description: Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
Home Page: www.revbiosciences.com
REVB Technical Analysis
4660 La Jolla Village Drive
San Diego,
CA
92122
United States
Phone:
650-800-3717
Officers
| Name | Title |
|---|---|
| Mr. James M. Rolke | CEO & Director |
| Mr. Chester Stanley Zygmont III | Chief Financial Officer |
| Ms. Sandra Vedrick | VP of HR & Investor Relations |
| Ms. Carol Odle | Sr. Director of Clinical Projects |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 7.7942 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8909 |
| Price-to-Sales TTM: | 2.8821 |
| IPO Date: | 2020-11-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |